乳果糖呼气试验预测腹泻型肠易激综合征患者对利福昔明的应答
多中心开放标签研究纳入93例腹泻型肠易激综合征(IBS-D)成人,接受利福昔明550mg每日三次共2周。基线乳果糖呼气试验(LBT)阳性者应答率59.7%,阴性者25.8%(P=0.002;OR 4.3,95%CI 1.5-12.7)。基线LBT阳性可预测利福昔明应答,提示肠道菌群调节机制。
要点
- 基线LBT阳性IBS-D患者利福昔明应答率显著高于阴性者(59.7% vs 25.8%)。
- 基线LBT阳性者6/7项IBS症状改善更显著。
- 治疗后LBT结果与临床应答不相关,但LBT正常化者应答率最高(76.5%)。
核心结论
- 基线乳果糖呼气试验阳性可预测IBS-D患者对利福昔明的更高应答可能性。
研究设计与样本
- 多中心前瞻性开放标签研究,13个中心参与,93例IBS-D成人接受利福昔明550mg每日三次共2周,治疗后随访4周。
主要发现
- 总体应答率48.4%(45/93);基线LBT阳性者应答率59.7%(37/62),阴性者25.8%(8/31),P=0.002,OR 4.3(95%CI 1.5-12.7)。
- 基线LBT阳性者在7项IBS症状中有6项较基线改善显著更优。
- 治疗后LBT结果与临床应答不相关(86例可评估,P=0.21);但LBT正常化者应答率最高,为76.5%(13/17)。
临床怎么用
- 基线LBT阳性可能有助于识别更可能从利福昔明获益的IBS-D患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The nonsystemic antibiotic rifaximin is indicated for irritable bowel syndrome with diarrhea (IBS-D) in adults; however, determinants of response remain unclear. The utility of lactulose breath testing (LBT) in predicting response to rifaximin was examined. METHODS: Adults with IBS-D received open-label rifaximin 550 mg 3 times daily for 2 weeks, followed by a 4-week posttreatment assessment period. Thirteen centers prospectively participated in this substudy. LBT was conducted before (day 1) and after (day 14) therapy (breath samples obtained every 15 minutes; up to 240 minutes). Patient response (decrease from baseline of ≥30% in abdominal pain and ≥50% decrease in frequency of mushy/watery stool), symptom improvement, and the relationship of clinical outcomes to LBT results were assessed. RESULTS: A total of 93 patients were included; 62 (66.7%) had positive baseline LBT results. Overall, 48.4% (45/93) of patients responded to rifaximin; of these, 59.7% (37/62) had a positive baseline LBT vs 25.8% (8/31) with a negative LBT (P = 0.002; odds ratio 4.3, 95% confidence interval, 1.5-12.7). Patients with a positive baseline LBT result experienced significantly greater improvement from baseline in 6 of 7 individual IBS symptoms. LBT results after rifaximin therapy did not correlate with clinical response in the 86 patients with evaluable breath tests (P = 0.21); however, patients whose LBT results normalized after rifaximin had the highest response rate of 76.5% (13/17). DISCUSSION: A positive baseline LBT result predicted a higher likelihood of response to rifaximin in IBS-D, suggesting a gut microbiome modulatory mechanism of action for rifaximin.
引用
- Rezaie A, Heimanson Z, McCallum R, et al. Lactulose Breath Testing as a Predictor of Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea. Am J Gastroenterol. 2019. PMID: 31688023. doi:10.14309/ajg.0000000000000444
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。